Literature DB >> 7482434

Mechanism of inhibition of fibrinolysis and fibrinogenolysis by the end fibrinogen degradation products.

L S Khavkina1, M A Rozenfeld, V B Leonova.   

Abstract

Influence of the end fibrinogen-derived DH, DL and E fragments on fibrinolysis and fibrinogenolysis has been studied. Electrophoresis of the plasmin-digested unstabilized fibrin and fibrinogen showed that fragment E was the only inhibitor of plasmin hydrolysis of fibrinogen, the antifibrinolytic activity of the fragments being increased in a DL < E < DH series. The fragments were revealed by means of elastic light scattering and analytical ultracentrifugation to be arranged in a E > DL > DH series by their ability to form a complex with plasminogen. It was concluded that the complex formation did not greatly contribute to the mechanism of fibrinolysis inhibition. Antifibrinolytic effect of fragment DH is due to its antipolymerization activity. The paper discusses the competitive protein-protein interactions occurring on a polymeric matrix of fibrin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7482434     DOI: 10.1016/0049-3848(95)00045-3

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  3 in total

1.  Free-radical oxidation of fibrinogen fragments D and E.

Authors:  M A Rozenfeld; V B Leonova; A N Shegolihin; S D Razumovskii; M L Konstantinova; A V Bychkova; A L Kovarskii
Journal:  Dokl Biochem Biophys       Date:  2010-08-17       Impact factor: 0.788

2.  Oxidative modification of fibrinogen molecules.

Authors:  M A Rosenfeld; A N Shegolihin; A V Bychkova; V B Leonova; M I Biryukova; E A Kostanova; M L Konstantinova
Journal:  Dokl Biochem Biophys       Date:  2013-10-23       Impact factor: 0.788

3.  Induction of Tissue Factor Pathway Inhibitor 2 by hCG Regulates Periovulatory Gene Expression and Plasmin Activity.

Authors:  Muraly Puttabyatappa; Linah F Al-Alem; Farnosh Zakerkish; Katherine L Rosewell; Mats Brännström; Thomas E Curry
Journal:  Endocrinology       Date:  2017-01-01       Impact factor: 4.736

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.